Bi Ke, Cheng Gang, Wu Xiuyin, Lv Zhijun
Department of Stomatology, Affiliated People's Hospital of Shandong First Medical University, Jinan, People's Republic of China.
Ther Clin Risk Manag. 2025 Apr 23;21:523-532. doi: 10.2147/TCRM.S518989. eCollection 2025.
To investigate the effect of combining intra-articular injection of hyaluronic acid (HA) with occlusal splint therapy in the treatment of non-reducible anterior disc displacement of the temporomandibular joint (ADDWoR).
A retrospective analysis was conducted on the clinical data of 62 patients with ADDWoR admitted to our hospital from April 2023 to June 2024. According to the treatment method received, patients were divided into a control group (n=31, treated with occlusal splints) and an observation group (n=31, treated with occlusal splints combined with intra-articular injection of HA). The clinical treatment effects, pain levels (Visual Analog Scale [VAS]), temporomandibular joint dysfunction (Friction Temporomandibular Joint Dysfunction Index [CMI]), mandibular movement function (maximum mouth opening [MMO], left lateral excursion [LLE], right lateral excursion [RLE], protrusive movement [PM]), clinical aesthetic indicators (condylar height, joint space width), and adverse reactions were compared between the two groups.
(1) Clinical Efficacy: The observation group had a higher total effective rate (90.32% vs 67.74%, P < 0.05). (2) Pain & Dysfunction: Both groups showed significant improvement in VAS and CMI scores over time, with the observation group exhibiting greater reductions (P < 0.05). (3) Mandibular Function & Aesthetic Indicators: The observation group had greater improvements in MMO, LLE, RLE, PM, condylar height, and joint space width (P < 0.05). (4) Adverse Reactions: No significant difference in adverse reaction rates (P > 0.05).
The combination of intra-articular injection of HA with occlusal splint therapy can further improve the treatment outcomes for ADDWoR patients, alleviate pain, improve temporomandibular joint dysfunction and mandibular movement function, promote aesthetic recovery, and does not increase the risk of adverse reactions.
探讨关节腔内注射透明质酸(HA)联合牙合垫治疗颞下颌关节不可复性盘前移位(ADDWoR)的效果。
回顾性分析2023年4月至2024年6月我院收治的62例ADDWoR患者的临床资料。根据接受的治疗方法,将患者分为对照组(n=31,采用牙合垫治疗)和观察组(n=31,采用牙合垫联合关节腔内注射HA治疗)。比较两组的临床治疗效果、疼痛程度(视觉模拟评分法[VAS])、颞下颌关节功能障碍(摩擦性颞下颌关节功能障碍指数[CMI])、下颌运动功能(最大张口度[MMO]、左侧侧方运动[LLE]、右侧侧方运动[RLE]、前伸运动[PM])、临床美学指标(髁突高度、关节间隙宽度)及不良反应。
(1)临床疗效:观察组总有效率较高(90.32%对67.74%,P<0.05)。(2)疼痛与功能障碍:两组VAS和CMI评分均随时间显著改善,观察组改善幅度更大(P<0.05)。(3)下颌功能与美学指标:观察组在MMO、LLE、RLE、PM、髁突高度和关节间隙宽度方面改善更明显(P<0.05)。(4)不良反应:不良反应发生率差异无统计学意义(P>0.05)。
关节腔内注射HA联合牙合垫治疗可进一步提高ADDWoR患者的治疗效果,缓解疼痛,改善颞下颌关节功能障碍和下颌运动功能,促进美学恢复,且不增加不良反应风险。